Innate Pharma
Re: Innate Pharma
beursfre liked last!57% ETF:C50,CP9,SXRW,IWDA,CSSPX,ICHN,NDIA,IBCJ,WSML,XMLC,OMXH25,WVAL,SMH,D5BH,WTAI,SGLD
28% Value:AGS,APT,BGFV,BCC,BPOST,1113,ECONB,EVS,FKWL,HEIJ,IAG,KBCA,LOG,MOUR,MYTIL,BNB,NN,PROX,QIWI
12% Obligatie
4% Casino
28% Value:AGS,APT,BGFV,BCC,BPOST,1113,ECONB,EVS,FKWL,HEIJ,IAG,KBCA,LOG,MOUR,MYTIL,BNB,NN,PROX,QIWI
12% Obligatie
4% Casino
Laatste artikelen op Beursig.com
Beleggen in bitcoin en ethereum op Euronext beurs
Wild west taferelen bij aandelen, crypto valuta en ...
Volg Beursig.com
Re: Innate Pharma
oeps sta plots +10%. 
Laat maar gaan.
Laat maar gaan.
Re: Innate Pharma
BTW, zelfde verhaal bij Transgene, nog zo een Franse parel in mijn portefeuille, stijgt momenteel met 15%.
57% ETF:C50,CP9,SXRW,IWDA,CSSPX,ICHN,NDIA,IBCJ,WSML,XMLC,OMXH25,WVAL,SMH,D5BH,WTAI,SGLD
28% Value:AGS,APT,BGFV,BCC,BPOST,1113,ECONB,EVS,FKWL,HEIJ,IAG,KBCA,LOG,MOUR,MYTIL,BNB,NN,PROX,QIWI
12% Obligatie
4% Casino
28% Value:AGS,APT,BGFV,BCC,BPOST,1113,ECONB,EVS,FKWL,HEIJ,IAG,KBCA,LOG,MOUR,MYTIL,BNB,NN,PROX,QIWI
12% Obligatie
4% Casino
Re: Innate Pharma
de traders voor 0,5cent hebben weer plezier gehad in US
40m stuks verhandeld
eindkoers 6,15$ (5,18€)
niet hopen dat maandag die richting uitgaat
Europa volgt nooit op us met Euro aandelen (is mijn ervaring)
40m stuks verhandeld
eindkoers 6,15$ (5,18€)
niet hopen dat maandag die richting uitgaat
Europa volgt nooit op us met Euro aandelen (is mijn ervaring)
Re: Innate Pharma
moeilijke prijsvorming…
nog geen handel…
146000 stuks staan bij de bid…
nog geen handel…
146000 stuks staan bij de bid…
Re: Innate Pharma
Winst genomen. Alles verkocht 4,67.
+ 15% netto.
+ 15% netto.
Re: Innate Pharma
raar aandeelke toch….
+13% vandaag….
twijfel om uit te stappen
maar zo stijgen zonder echt iets nieuws…
+13% vandaag….
twijfel om uit te stappen
maar zo stijgen zonder echt iets nieuws…
Re: Innate Pharma
bericht van 2 september
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress.
AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, highlighting progression-free survival (PFS) results for novel durvalumab combinations with potential new medicines, including Innate’s monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, in unresectable, Stage III non-small cell lung cancer (NSCLC). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
In addition, Innate will present pre-clinical data from its next-generation, proprietary, multi-specific NK cell engager platform known as ANKETTM (Antibody-based NK cell Engager Therapeutics).
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress.
AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, highlighting progression-free survival (PFS) results for novel durvalumab combinations with potential new medicines, including Innate’s monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, in unresectable, Stage III non-small cell lung cancer (NSCLC). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
In addition, Innate will present pre-clinical data from its next-generation, proprietary, multi-specific NK cell engager platform known as ANKETTM (Antibody-based NK cell Engager Therapeutics).
Re: Innate Pharma
op dat bericht schoten ze vorige week van 3,10 naar 3,9 ofzo….NewB76 schreef: ↑09 sep 2021 16:55bericht van 2 september
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress.
AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, highlighting progression-free survival (PFS) results for novel durvalumab combinations with potential new medicines, including Innate’s monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, in unresectable, Stage III non-small cell lung cancer (NSCLC). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
In addition, Innate will present pre-clinical data from its next-generation, proprietary, multi-specific NK cell engager platform known as ANKETTM (Antibody-based NK cell Engager Therapeutics).
dat congres is volgende week
